Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Deepak R Jadon"'
Autor:
Tania Gudu, Beverly Ng, Hannah Jethwa, Catherine Graham, Veda Kudva, Jashmitha Rammanohar, Chen Zhang, Mark Sapsford, Deepak R. Jadon
Publikováno v:
Frontiers in Medicine, Vol 8 (2022)
Objective: Despite recent advances, early diagnosis of psoriatic arthritis (PsA) remains a challenge in clinical practice. Ultrasound (US) could be a useful tool for the diagnosis and management of PsA. The objective of this review was to determine t
Externí odkaz:
https://doaj.org/article/4129757580e6474fab7c25ba93181008
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Aims: The ability to predict response to treatment remains a key unmet need in psoriatic disease. We conducted a systematic review of studies relating to biomarkers associated with response to treatment in either psoriasis vulgaris (PsV) or psoriatic
Externí odkaz:
https://doaj.org/article/3c047bda5a4644a2a618513f7f98bb74
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Background: Patients with inflammatory bowel disease (IBD) have an excess burden of axial spondyloarthritis (axSpA), which, if left untreated, may significantly impact on clinical outcomes. We aimed to estimate the prevalence of axSpA, including prev
Externí odkaz:
https://doaj.org/article/ae8944650d13441da3c55d48cccdd7b7
Autor:
Tania Gudu, Deepak R. Jadon
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 12 (2020)
Multidisciplinary (MD) care is essential in the management of patients with spondyloarthritis (SpA) and is one of the main pillars of disease management and patient care. However, evidence supporting the effectiveness and benefits of this strategy in
Externí odkaz:
https://doaj.org/article/5f3aaf906f3342f2bd3d1e0beb22e95c
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 12 (2020)
Depression is a major neuropsychiatric disorder common in patients with rheumatological conditions including spondyloarthritis (SpA). It is associated with higher disease activity, functional impairment, poor treatment response and quality of life in
Externí odkaz:
https://doaj.org/article/1d6e45960fbc4e0897ff4ba3b3ddfae8
Autor:
Deepak R. Jadon, Raj Sengupta, Alison Nightingale, Hui Lu, Juliet Dunphy, Amelia Green, James T. Elder, Rajan P. Nair, Eleanor Korendowych, Mark A. Lindsay, Neil J. McHugh
Publikováno v:
Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-10 (2017)
Abstract Background A recent systematic review identified four candidate serum-soluble bone-turnover biomarkers (dickkopf-1, Dkk-1; macrophage-colony stimulating factor, M-CSF; matrix metalloproteinase-3, MMP-3; osteoprotegerin, OPG) showing possible
Externí odkaz:
https://doaj.org/article/87364c68f7484d8095e034bba7aba577
Autor:
Poonam Sharma, Deepak R Jadon, Dennis McGonagle, Barbara Ink, Deepak Assudani, Vanessa Taieb, Laura C Coates
Publikováno v:
Rheumatology. 62
Background/Aims Bimekizumab (BKZ) is a humanised monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A and has demonstrated clinical effectiveness in both joint and skin outcomes in patients with active psoriatic arthritis (
Autor:
Deepak R. Jadon, Nadia Corp, Danielle A. van der Windt, Laura C. Coates, Enrique R. Soriano, Arthur Kavanaugh, Tim Raine, Florian Rieder, Stefan Siebert, Michel Zummer, Sergio Schwartzman, James T. Rosenbaum, Brigitte Michelsen, Ramasharan Laxminarayan, Dongze Wu, Latika Gupta, Beverly Ng, Hannah Jethwa, Nick De Windt, Tania Gudu, Joseph Hutton, Denis O'Sullivan, Michele M. Luchetti, Matthew Stoll, Jasvinder A. Singh, Rosario Peluso, Judith Rademacher, M. Elaine Husni
Publikováno v:
The Journal of rheumatology.
ObjectiveSeveral advanced therapies have been licensed across the related conditions of psoriatic arthritis (PsA), Crohn disease (CD), ulcerative colitis (UC), and noninfectious uveitis. We sought to summarize results from randomized controlled trial
Autor:
William Tillett, Iain B McInnes, Dennis McGonagle, Deepak R Jadon, Barbara Ink, Deepak Assudani, Jason Coarse, Jason Eells, Laura C Coates
Publikováno v:
Rheumatology. 61
Background/Aims Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL17A, has demonstrated an acceptable safety profile with improvements in joint and skin outcomes to 3 years in patients with active psor
Publikováno v:
SEMINARS IN ARTHRITIS AND RHEUMATISM
Psoriatic arthritis (PsA) is a heterogenous, chronic, inflammatory musculoskeletal disease that can lead to peripheral and axial damage and loss of function. Axial involvement occurs in 25% to 70% of patients with PsA, varying greatly depending on it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32419c3809616d14e195239636fab35